BRPI0812875B8 - " método in vitro para indentificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, e, kit de teste - Google Patents

" método in vitro para indentificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, e, kit de teste

Info

Publication number
BRPI0812875B8
BRPI0812875B8 BRPI0812875A BRPI0812875A BRPI0812875B8 BR PI0812875 B8 BRPI0812875 B8 BR PI0812875B8 BR PI0812875 A BRPI0812875 A BR PI0812875A BR PI0812875 A BRPI0812875 A BR PI0812875A BR PI0812875 B8 BRPI0812875 B8 BR PI0812875B8
Authority
BR
Brazil
Prior art keywords
individual
risk
severe sepsis
test kit
vitro method
Prior art date
Application number
BRPI0812875A
Other languages
English (en)
Inventor
Björck Lars
Christensson Bertil
Herwald Heiko
Linder Adam
Äkesson Per
Original Assignee
Hansa Medical Ab
Hansa Biopharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38331957&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0812875(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hansa Medical Ab, Hansa Biopharma AB filed Critical Hansa Medical Ab
Publication of BRPI0812875A2 publication Critical patent/BRPI0812875A2/pt
Publication of BRPI0812875B1 publication Critical patent/BRPI0812875B1/pt
Publication of BRPI0812875B8 publication Critical patent/BRPI0812875B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

MÉTODO IN VITRO PARA IDENTIFICAR SE OU NÃO UM INDIVÍDUO ESTÁ SOB RISCO DE DESENVOLVIMENTO DE SÉPSIS SEVERA, E, KIT DE TESTE. Tem sido demonstrado que o nível de HBP aumenta em indivíduos que subseguentemente desenvolvem sépsis severa. Conformemente, o nível de HBP, a razão de HBP/WBC ou a razão de HBP/NC em um indivíduo podem ser usados para determinar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa.
BRPI0812875A 2007-06-12 2008-06-12 " método in vitro para indentificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, e, kit de teste BRPI0812875B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0711327.7A GB0711327D0 (en) 2007-06-12 2007-06-12 Diagnostic method
GB0711327.7 2007-06-12
PCT/EP2008/004743 WO2008151808A1 (en) 2007-06-12 2008-06-12 Diagnostic method

Publications (3)

Publication Number Publication Date
BRPI0812875A2 BRPI0812875A2 (pt) 2014-12-09
BRPI0812875B1 BRPI0812875B1 (pt) 2017-12-05
BRPI0812875B8 true BRPI0812875B8 (pt) 2022-07-12

Family

ID=38331957

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812875A BRPI0812875B8 (pt) 2007-06-12 2008-06-12 " método in vitro para indentificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, e, kit de teste

Country Status (16)

Country Link
US (3) US8518648B2 (pt)
EP (1) EP2129391B1 (pt)
JP (1) JP5166522B2 (pt)
KR (1) KR101563997B1 (pt)
CN (2) CN101687023B (pt)
AT (1) ATE548050T1 (pt)
AU (1) AU2008261252B2 (pt)
BR (1) BRPI0812875B8 (pt)
CA (1) CA2690067C (pt)
DK (1) DK2129391T3 (pt)
ES (1) ES2380875T3 (pt)
GB (1) GB0711327D0 (pt)
PL (1) PL2129391T3 (pt)
PT (1) PT2129391E (pt)
SI (1) SI2129391T1 (pt)
WO (1) WO2008151808A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0711327D0 (en) 2007-06-12 2007-07-25 Hansa Medical Ab Diagnostic method
US20100240049A1 (en) 2009-01-16 2010-09-23 Cepheid Methods of Detecting Cervical Cancer
JP5488885B2 (ja) * 2009-10-28 2014-05-14 国立大学法人 東京大学 感染症の疾患マーカー
GB201016161D0 (en) * 2010-09-24 2010-11-10 Hansa Medical Ab Diagnostic method
WO2012068642A1 (en) * 2010-11-26 2012-05-31 Immunexpress Pty Ltd Diagnostic and/or screening agents and uses therefor
GB201102108D0 (en) * 2011-02-07 2011-03-23 Hansa Medical Ab Diagnostic method
CA2848873A1 (en) * 2011-09-16 2013-03-21 Cepheid Methods of detecting sepsis
US10260111B1 (en) 2014-01-20 2019-04-16 Brett Eric Etchebarne Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample
US10761093B2 (en) 2014-10-09 2020-09-01 Texas Tech University System Microdevice for cell separation utilizing activation phenotype
CN109541235A (zh) * 2018-08-19 2019-03-29 重庆早柒天生物科技股份有限公司 肝素结合蛋白和降钙素原二联检测试剂盒及其制备方法
US20220178932A1 (en) 2019-04-24 2022-06-09 Japanese Foundation For Cancer Research Cancer detection method and detection reagent
CN111208305B (zh) * 2020-02-16 2023-04-25 重庆翼锋生物科技有限公司 Hbp和pct在败血症诊断试剂制备中的用途
CN111951963B (zh) 2020-07-30 2022-09-02 中翰盛泰生物技术股份有限公司 Hbp在covid-19患者的预后风险预警中的应用
JP2024516677A (ja) * 2021-04-30 2024-04-16 エフ． ホフマン－ラ ロシュ アーゲー 敗血症の早期検出用のｎｇａｌマーカーパネル
CN117242350A (zh) * 2021-04-30 2023-12-15 豪夫迈·罗氏有限公司 用于脓毒症的早期检测的il6标志物组
CN117280218A (zh) * 2021-04-30 2023-12-22 豪夫迈·罗氏有限公司 用于脓毒症的早期检测的strem1标志物组

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627262A (en) 1989-07-05 1997-05-06 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
US5962241A (en) * 1989-07-28 1999-10-05 The University Of Arizona Monoclonal antibody detection of proteins on sperm related to fertility
US5314804A (en) * 1992-03-24 1994-05-24 Serim Research Corporation Test for Helicobacter pylori
RU2200573C2 (ru) 1994-04-21 2003-03-20 Леукотех А/С Связывающий гепарин белок для лечения сепсиса
US5976536A (en) 1995-08-09 1999-11-02 Emory University Neisseria mutants, lipooligosaccharides and immunogenic compositions
US5778895A (en) 1997-01-29 1998-07-14 Uab Research Foundation Method of discriminating bacterial from aseptic meningitis
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7655480B2 (en) 2002-03-08 2010-02-02 The Board Of Regents Of The University Of Oklahoma Method for predicting sepsis or an acute infectious inflammatory response
AU2003220034A1 (en) 2002-03-08 2003-09-22 Heloise, Anne, Pereira, Ph. D. An early detection marker for chronic inflammatory associated diseases
EP1581556A2 (en) 2002-08-15 2005-10-05 Leukotech A/S Bactericidal, anti-apoptotic, pro-inflammatory and anti-inflammatory peptides of heparin-binding protein (hbp)
JP2006515227A (ja) * 2003-02-24 2006-05-25 ジーティーシー バイオセラピューティックス インコーポレイテッド 十字流濾過の方法およびそのための装置
US7191068B2 (en) 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
US20070110804A1 (en) * 2003-06-20 2007-05-17 Royer Biomedical, Inc. Drug polymer complexes
EP1668034A1 (en) 2003-09-19 2006-06-14 Leukotech A/S Pro-inflammatory and anti-inflammatory antibodies against the heparin-binding protein (hbp)
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
US20070092911A1 (en) 2005-10-03 2007-04-26 Buechler Kenneth F Methods and compositions for diagnosis and /or prognosis in systemic inflammatory response syndromes
KR20080006617A (ko) * 2005-04-15 2008-01-16 백톤 디킨슨 앤드 컴퍼니 패혈증의 진단
FR2894675B1 (fr) 2005-12-14 2008-06-27 Assist Publ Hopitaux De Paris Distinction des meningites bacteriennes et virales
GB0711327D0 (en) 2007-06-12 2007-07-25 Hansa Medical Ab Diagnostic method
GB201016161D0 (en) 2010-09-24 2010-11-10 Hansa Medical Ab Diagnostic method
GB201102108D0 (en) 2011-02-07 2011-03-23 Hansa Medical Ab Diagnostic method

Also Published As

Publication number Publication date
ES2380875T3 (es) 2012-05-21
US9784741B2 (en) 2017-10-10
WO2008151808A1 (en) 2008-12-18
US20130252347A1 (en) 2013-09-26
EP2129391A1 (en) 2009-12-09
CN101687023B (zh) 2016-04-20
AU2008261252A1 (en) 2008-12-18
PL2129391T3 (pl) 2012-09-28
SI2129391T1 (sl) 2012-07-31
CA2690067C (en) 2023-09-19
DK2129391T3 (da) 2012-06-11
JP2010529468A (ja) 2010-08-26
KR101563997B1 (ko) 2015-10-28
US20140187503A1 (en) 2014-07-03
BRPI0812875A2 (pt) 2014-12-09
KR20100021578A (ko) 2010-02-25
PT2129391E (pt) 2012-06-06
EP2129391B1 (en) 2012-03-07
JP5166522B2 (ja) 2013-03-21
CN101687023A (zh) 2010-03-31
AU2008261252B2 (en) 2013-03-14
BRPI0812875B1 (pt) 2017-12-05
GB0711327D0 (en) 2007-07-25
ATE548050T1 (de) 2012-03-15
CN103543271A (zh) 2014-01-29
CA2690067A1 (en) 2008-12-18
US20100305185A1 (en) 2010-12-02
US8518648B2 (en) 2013-08-27

Similar Documents

Publication Publication Date Title
BRPI0812875A2 (pt) " método pra identificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, anticorpo específico para proteína ligante de heparina, método pra reduzir o risco de um indivíduo desenvolver sépsis severa, e, kit de teste ".
GB2477877A (en) Colorimetric test for brake system corrosion
BR112015004881A2 (pt) método para diagnosticar o estado da doença periodontal e kit para diagnosticar o estado da doença periodontal
EP2212700B8 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
BRPI1013688A8 (pt) Proteínas de ligação de il-17.
BRPI0720361A8 (pt) Método para medir aglutinação de uma ou mais partículas em um ensaio de aglutinação induzida por alvo efetuado em uma câmara de reação, e, kit e dispositivo para medir um ou mais parâmetros de aglutinação de partículas em um ensaio de aglutinação induzida por alvo
BRPI0911067B8 (pt) métodos e sistemas para determinar a presença ou ausência de um analito em uma amostra de líquido
WO2007143211A3 (en) Methods for identifying agents and their use for the prevention of restenosis
BR112022007386A2 (pt) Métodos para tratar um câncer hematológico e o uso de biomarcadores companheiros para 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)isoindolina-1,3-diona
WO2009023331A3 (en) Antibodies and improved test sample handling methods for use in assays for myeloperoxidase
Loria et al. Sex‐specific alterations in NOS regulation of vascular function in aorta and mesenteric arteries from spontaneously hypertensive rats compared to Wistar Kyoto rats
PE20141450A1 (es) Ensayo de lisiloxidasa-homologo 2 y metodos de uso del mismo
DiRocco et al. A role for calmodulin-stimulated adenylyl cyclases in cocaine sensitization
WO2005031005A3 (en) Compositions, methods and kits for determining the presence of trichomonas vaginalis in a test sample
ATE420374T1 (de) Automatisches testsystem mit leicht modifizierter software
BRPI0807601B8 (pt) método para identificação de um paciente que esteja em risco com relação ao desenvolvimento de um distúrbio na tireoide e uso de um agente depletivo de linfócitos
EP1718768A4 (en) METHOD AND COMPOSITIONS FOR DETERMINING A TRANSPLANT-TOLERANT PHENOTYPE IN AN INDIVIDUAL
BR112022003869A2 (pt) Método não invasivo para quantificar função renal e declínio funcional
MX2021009281A (es) Metodos de deteccion de legionella.
FR2900936B1 (fr) Procede et methodes de detection de la maladie d'alzheimer
ATE467128T1 (de) Kolloidale metallkonjugate
Pacheco et al. Optimization of a filter‐lysis protocol to purify rat testicular homogenates for automated spermatid counting
ES2571929T3 (es) Procedimiento para determinar la cantidad de CD36 circulante
PL426138A1 (pl) Sposób diagnozowania boreliozy, sposób różnicowego diagnozowania boreliozowego zapalenia stawów, lizofosfatydyloetanoloamina do zastosowania jako biomarker, zestaw do diagnozowania boreliozy i zestaw do różnicowego diagnozowania boreliozowego zapalenia stawów
CL2011000363A1 (es) Metodo para identificar predisposicion a hepatotoxicidad mediante el alelo hla dqa1*0102, drb1*1501, dqb1*0602, drb5*0101; uso de sonda que detecta el alelo para determinar la susceptibilidad a desarrollar hepatotoxicidad luego de administrar lumiracobix; uso de lumiracobix para tratamiento de trastornos mediados por cox-2.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B25D Requested change of name of applicant approved